- Home
- DNTH vs IDCC Comparison
DNTH vs IDCC Comparison
Compare DNTH & IDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | IDCC |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.6B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DNTH | IDCC |
|---|---|---|
| Price | $111.10 | $342.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | $121.00 | ★ $412.50 |
| AVG Volume (30 Days) | ★ 718.6K | 224.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.51 |
| Revenue | $2,036,000.00 | ★ $307,404,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.48 | $3.38 |
| P/E Ratio | ★ N/A | $62.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.81 | $249.14 |
| 52 Week High | $117.88 | $412.60 |
Technical Indicators
Market Signals| Indicator | DNTH | IDCC |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 65.18 |
| Support Level | $79.27 | $315.71 |
| Resistance Level | $114.55 | $369.35 |
| Average True Range (ATR) | 5.11 | 11.34 |
| MACD | -0.55 | -0.03 |
| Stochastic Oscillator | 42.67 | 78.17 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About IDCC InterDigital Inc.
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.